Empirical meropenem versus piperacillin/tazobactam for adult patients with sepsis (<scp>EMPRESS</scp>) trial: Protocol
Anders Granholm(University of Copenhagen), Morten Hylander Møller(University of Copenhagen), Marie Warrer Munch(University of Copenhagen), Frederik Boëtius Hertz(University of Copenhagen), Anders Perner(Unknown), Jakob Steen Andersen(Copenhagen University Hospital), Nick Meier(Copenhagen University Hospital), Benjamin Skov Kaas‐Hansen(Copenhagen University Hospital), Trine Albertsen(Syddansk Innovation (Denmark)), Theis Lange(Aalborg University), Maj‐Brit Nørregaard Kjær(Copenhagen University Hospital), Lars W. Andersen(University of Copenhagen), Aksel Karl Georg Jensen(University of Copenhagen), Bodil Steen Rasmussen, Hans‐Christian Thorsen‐Meyer(University of Copenhagen), Fredrik Sjövall(Skåne University Hospital), Marie Helleberg(Rigshospitalet)
Cited by 5
Related Papers
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
|Intensive Care Medicine|2017|6.8k
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
|Intensive Care Medicine|2021|5.1k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
|Critical Care Medicine|2017|3.8k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021
|Critical Care Medicine|2021|2.8k